Voting in the 2020 election (AP Images)

The right to vote is fun­da­men­tal — a let­ter from biotech­nol­o­gy in­dus­try lead­ers

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

We op­pose all at­tempts to in­tro­duce laws that re­duce the rights of US cit­i­zens to vote or that re­strict them from ex­er­cis­ing that right. The right to vote is fun­da­men­tal to democ­ra­cy. States that have en­act­ed, or are propos­ing to en­act, leg­is­la­tion to re­strict vot­ing are un­der­min­ing our democ­ra­cy and pos­ing a threat to our na­tion. As lead­ers of the life sci­ences in­dus­try, we stand for what we be­lieve is right for our coun­try, our en­ter­pris­es, our em­ploy­ees and those who ben­e­fit from our work. We join the first groups of busi­ness lead­ers who have chal­lenged these laws and will con­tin­ue to make our col­lec­tive voic­es heard on this mat­ter.

In some cas­es, in­sti­ga­tors of such laws may be sin­cere in be­liev­ing they are “en­sur­ing in­tegri­ty of the vot­ing process.” Such be­liefs are based on the con­tention that the 2020 elec­tion was “fraud­u­lent.” The US courts, the De­part­ment of Jus­tice, var­i­ous state gov­ern­ment of­fices and in­de­pen­dent in­ves­ti­ga­tions all have de­bunked this myth. In oth­er cas­es, pro­po­nents of such laws co­or­di­nate ef­forts and de­lib­er­ate­ly seek to dis­en­fran­chise and dis­crim­i­nate against par­tic­u­lar vot­ers.

Through­out its his­to­ry, Amer­i­ca has been called on re­peat­ed­ly to re­new and ad­vance its com­mit­ment to its found­ing ideals. Core among these is that all Amer­i­cans are en­ti­tled to equal op­por­tu­ni­ty and to be treat­ed equal­ly un­der the law. There is noth­ing more in­im­i­cal to these ideals than to un­der­mine our right to vote in free and fair elec­tions.

Amer­i­cans have en­dured a ter­ri­ble Civ­il War and have fought for gen­er­a­tions to over­come the evils of slav­ery, seg­re­ga­tion and Jim Crow. To­day we are fac­ing an­oth­er im­por­tant chap­ter in this fight. The cur­rent ef­forts in sev­er­al states to change vot­ing laws ef­fec­tive­ly mar­gin­al­ize and sup­press par­tic­u­lar class­es of vot­ers. Such out­comes fur­ther di­vide our so­ci­ety. They lead us back­ward, un­rav­el­ing many of the hard-won vic­to­ries — for which Amer­i­cans fought, and of­ten died — crit­i­cal to our na­tion’s democ­ra­cy and the free­dom of fu­ture gen­er­a­tions.

The biotech­nol­o­gy in­dus­try is dri­ving a rev­o­lu­tion to cure pa­tients, pro­tect our cli­mate, and nour­ish hu­man­i­ty. Our in­dus­try im­pacts the lives of bil­lions, em­ploys and in­vests in every state in our na­tion, and leads the de­vel­op­ment of vac­cines and med­i­cines that will de­feat the glob­al Covid pan­dem­ic and many oth­er dis­eases.

The US leads the world in biotech­nol­o­gy in large part be­cause the sci­ence un­der­pin­ning our in­dus­try thrives in a free so­ci­ety. Peo­ple of tal­ent are drawn to our in­dus­try re­gard­less of their per­son­al iden­ti­fiers or na­tion­al­i­ty. They feel that they will in­deed have equal op­por­tu­ni­ty to con­tribute and suc­ceed. They be­lieve they will be treat­ed equal­ly by the law and that ef­forts to con­tribute to the biotech­nol­o­gy rev­o­lu­tion are fos­tered by the so­ci­ety we live in. When the 2 free­doms foun­da­tion­al to our so­ci­ety are abridged, we lose this ad­van­tage, and will cede the field and our in­no­va­tions to com­pet­ing coun­tries.

As lead­ers in the biotech­nol­o­gy in­dus­try, and as in­di­vid­u­als who care deeply about democ­ra­cy, we call on all lead­ers in our in­dus­try to act as fol­lows:

  1. When mak­ing new or ad­di­tion­al cap­i­tal in­vest­ments, ac­tive­ly con­sid­er al­ter­na­tives to in­vest­ing with­in states that have en­act­ed vot­er sup­pres­sion laws.
  2. En­cour­age or­ga­niz­ers to con­sid­er al­ter­na­tive venues for con­fer­ences and ma­jor meet­ings and re­spect the right of those who choose not to at­tend meet­ings in any State en­act­ing vot­er sup­pres­sion laws.
  3. Es­tab­lish poli­cies per­mit­ting half-day paid leave for all em­ploy­ees to vote.
  4. En­cour­age em­ploy­ees to par­tic­i­pate in ef­forts to help reg­is­ter vot­ers and phys­i­cal­ly as­sist those who are un­able to eas­i­ly vote them­selves due to age, ill­ness, dis­abil­i­ty or oth­er im­ped­i­ment

We stand to­geth­er for the rights of all Amer­i­cans to vote freely and fair­ly. To do oth­er­wise would be to ac­cede to the hol­low­ing out of our democ­ra­cy which, as Lin­coln ob­served, has made Amer­i­ca the “last, best hope on earth.” The sig­na­tures be­low rep­re­sent the views of in­di­vid­u­als and not their com­pa­nies or oth­er or­ga­ni­za­tions.

Signed,

Je­re­my Levin, DPhil, MB BChir, Chair­man and CEO, Ovid Ther­a­peu­tics

Paul Hast­ings, Pres­i­dent and CEO, Nkar­ta Ther­a­peu­tics

John Maraganore, CEO, Al­ny­lam Phar­ma­ceu­ti­cals

Ted W. Love, MD, Pres­i­dent and CEO, Glob­al Blood Ther­a­peu­tics

Rachel K. King, CEO, Gly­coMimet­ics

Ron Co­hen, MD, Pres­i­dent and CEO, Acor­da Ther­a­peu­tics

Sri­ni Akkara­ju, Founder & Man­ag­ing Part­ner, Sam­sara Bio­cap­i­tal

Jeff Al­bers, CEO, Blue­print Med­i­cines

Faraz Ali, CEO, Tenaya Ther­a­peu­tics

Theodore (Ted) T. Ash­burn, MD, PhD, Pres­i­dent and CEO, On­corus

Mar­tin Babler, For­mer CEO, Prin­cip­ia

Je­re­my Ben­der, CEO, Day One Phar­ma­ceu­ti­cals

Nes­san Berming­ham, PhD Founder & CEO at Triplet Ther­a­peu­tics, Founder and Ex­ec Chair at Ko­r­ro Bio, Chair at Fs­tar Ther­a­peu­tics

Hans Bish­op, CEO, Grail

Kevin Bit­ter­man, Part­ner, At­las Ven­ture

Robert I. Blum, Pres­i­dent and CEO, Cy­to­ki­net­ics, Inc.

Bruce Booth, Part­ner, At­las Ven­ture

Daniel M. Brad­bury, Ex­ec­u­tive Chair­man, Equi­l­li­um

Pablo J. Cagnoni, MD, Pres­i­dent and CEO, Ru­bius Ther­a­peu­tics

Chip Clark, Pres­i­dent and CEO, Geno­cea Bio­sciences

Scott Clarke, CEO, Am­bagon Ther­a­peu­tics

Tony Coles, MD, Chair and CEO, Cerev­el Ther­a­peu­tics

Roger Crys­tal, MD, Pres­i­dent and CEO, Opi­ant Phar­ma­ceu­ti­cals

Rahul Dhan­da, Pres­i­dent and CEO, Sher­lock Bio­sciences

Doug Do­er­fler, Pres­i­dent and CEO, Max­Cyte

Di­pal Doshi, CEO, En­tra­da Ther­a­peu­tics

Er­ic Dube, CEO, Tra­vere Ther­a­peu­tics

Dou­glas Fam­brough, CEO, Dicer­na Phar­ma­ceu­ti­cals

Corey Fish­man, CEO, Iterum Ther­a­peu­tics

Jean-François Formela, Part­ner, At­las Ven­ture

Jacqua­lyn A. Fouse, CEO, Agios Phar­ma­ceu­ti­cals

Cedric Fran­cois, CEO, Apel­lis Phar­ma­ceu­ti­cals

Sean George, CEO, In­vi­tae

Deb Ger­aghty, PhD, Pres­i­dent and CEO, Anokion

Michael Glad­stone, Part­ner, At­las Ven­ture

San­dra Glucks­mann, PhD, Pres­i­dent and CEO, Cedil­la Ther­a­peu­tics

Jeff Goater, Chair­man of the Board, Sur­face On­col­o­gy

David Grayzel, MD, Part­ner, At­las Ven­ture

Bar­ry Greene, CEO, Sage Ther­a­peu­tics

Adam Gri­d­ley, CEO, Al­lay Ther­a­peu­tics

David Hal­lal, Chair­man and CEO, El­e­vate­Bio

Patrick Hines, MD/PhD, CEO, Func­tion­al Flu­idics

Steven Holtz­man, Chair, Board of Di­rec­tors, Camp4

Alex Kar­nal, Co-Founder and CIO, Braid­well

Per­ry Karsen, for­mer CEO, Cel­gene Cel­lu­lar Ther­a­peu­tics

Scott Koenig, MD, PhD, Pres­i­dent and CEO, Macro­Gen­ics

Pe­ter Kolchin­sky, Man­ag­ing Part­ner, RA Cap­i­tal

Samarth Kulka­rni, CEO, CRISPR Ther­a­peu­tics

Don­na LaVoie, CEO, LaVoieHealth­Science

Pablo Legor­re­ta, Founder and CEO, Roy­al­ty Phar­ma

Mark Levin, Part­ner, TRV

Will Lewis, Chair and CEO, In­smed

Gail Maderis, Pres­i­dent and CEO, An­ti­va Bio­sciences

Tahir Mah­mood, CEO and Founder, Ap­plied Mol­e­c­u­lar Trans­port

Jef­frey D. Mar­raz­zo, CEO, Spark Ther­a­peu­tics

Alex Mar­tin, CEO, Pal­la­dio Bio­sciences

Ken Mills, Pres­i­dent and CEO, RE­GENXBIO

Ken­neth I. Moch, Se­nior Ad­vi­sor to the Chair­man, Cen­ter for Glob­al Health In­no­va­tion and the Glob­al Health Cri­sis Co­or­di­na­tion

Michael M. Mor­ris­sey, Pres­i­dent and CEO, Ex­elix­is

Amit Mun­shi, CEO, Are­na Phar­ma­ceu­ti­cals

William J. Newell, CEO, Sutro Bio­phar­ma

John Or­win, Pres­i­dent and CEO, Atre­ca

Ju­lia Owens, PhD, Ex­ec­u­tive Chair­man, Mil­len­do Ther­a­peu­tics

Ste­lios Pa­padopou­los, PhD, Chair­man of the Board at Bio­gen, Ex­elix­is, Reg­u­lus Ther­a­peu­tics

An­tho­ny Quinn, MB, ChB, PhD, Pres­i­dent and CEO, Ae­glea Bio­Ther­a­peu­tics

Bill Rastet­ter, Chair­man at Neu­ro­crine Bio­sciences, Fate Ther­a­peu­tics, Daré Bio­science; San Diego Squared

Ronald C. Re­naud, Jr., CEO, Trans­late Bio

Ja­son P. Rhodes, Part­ner, At­las Ven­ture

Mar­tine A. Roth­blatt, PhD, Chair­per­son and CEO, Unit­ed Ther­a­peu­tics Cor­po­ra­tion

George Scan­gos, PhD, CEO, Vir Biotech­nol­o­gy

John A. Scar­lett, MD, Chair­man and CEO, Geron Cor­po­ra­tion

Ran­dall C. Schatz­man, PhD, Pres­i­dent and CEO, Bolt Ther­a­peu­tics

Jim Sci­bet­ta, CEO, Mav­er­ick

Paul J. Sekhri, Pres­i­dent and CEO, eGe­n­e­sis

RA Ses­sion II, Pres­i­dent, CEO, Founder, Taysha Gene Ther­a­pies

Lau­ra Shawver, CEO, Sil­ver­back Ther­a­peu­tics

Clay B. Sie­gall, PhD, Pres­i­dent and CEO, Seagen

Nan­cy Si­mon­ian, MD, CEO, Sy­ros Phar­ma­ceu­ti­cals

Eri­ka R. Smith, CEO, ReNetX Bio

Jean-Pierre Som­ma­dos­si, PhD, Chair­man and CEO, Atea Phar­ma­ceu­ti­cals

Robert Tep­per, Part­ner, Third Rock Ven­tures

Arthur Tzian­a­bos, PhD, Pres­i­dent and CEO, Ho­mol­o­gy Med­i­cines

Michel Vounatsos, CEO, Bio­gen

Rick E. Win­ning­ham, Chair­man and CEO, Ther­a­vance Bio­phar­ma US

Michael Yang, Pres­i­dent and CEO, Vi­a­Cyte

Brad­ford A. Za­kes, Pres­i­dent, CEO and Chair­man Cerev­ast Med­ical

Want to sign your name to this let­ter? Reach out to man­ag­ing ed­i­tor Kyle Blanken­ship at kyle@end­pointsnews.com.

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

15 LGBTQ lead­ers in bio­phar­ma; Paul Stof­fels’ Gala­pa­gos re­vamp; As­traZeneca catch­es up in AT­TR; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

A return to in-person conferences also marks a return to on-the-ground reporting. My colleagues Beth Synder Bulik and Nicole DeFeudis were on-site at Cannes Lions, bringing live coverage of pharma’s presence at the ad festival — accompanied by photos from Clara Bui, our virtual producer, that bring you right to the scene. You can find a recap (and links to all the stories) below.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

Joe Papa (Ryan Remiorz/The Canadian Press via AP, File)

Joe Pa­pa re­signs as chair of Bausch Health as bil­lion­aire John Paul­son takes over

Joe Papa, chair of Bausch Health, officially resigned on Thursday and the board appointed billionaire hedge fund manager John Paulson as the new chair, effective immediately.

The specialty pharma company sought to make clear that Papa’s abrupt departure “was not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

GSK says its drug for chron­ic hep B could ‘lead to a func­tion­al cure’ — but will it be alone or in com­bi­na­tion?

GSK, newly branded and soon-to-be demerged, shared interim results from its Phase II trial on its chronic hepatitis B treatment, one that it says has the “potential to lead to a functional cure.”

At a presentation at the EASL International Liver Congress, GSK shared that in around 450 patients who received its hep B drug bepirovirsen for 24 weeks, just under 30% had hepatitis B surface antigen and viral DNA levels that were too low to detect.

FDA un­veils new draft guid­ance to help with oligonu­cleotide ther­a­peu­tics de­vel­op­ment

While oligonucleotides, a wide variety of synthetically modified RNA or RNA/DNA hybrids that bind to a target RNA sequence to alter RNA and/or protein expression, have been winning approvals in recent years (e.g. Novartis’ cholesterol drug Leqvio), the regulatory agency is offering new draft guidance for those looking to follow a similar path.

The non-binding guidance, titled “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics Guidance for Industry” deals with pharmacokinetic, pharmacodynamic, and safety assessments required as part of oligonucleotide therapeutics R&D.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.